Options trading in Sellas Life Sciences Group Inc. reached 66,504 contracts by 2:10 p.m. New York time on Friday, according to exchange data compiled by Bloomberg.
Call activity accounted for most of the session, with 50,150 contracts changing hands, while put volume totaled 16,354 contracts.
Most active strikes and spreads
The single most-active option was the June 26, 2026 $12 call, which recorded 3,815 contracts traded against an open interest of 1,548 contracts. A paired strategy - a spread involving September 18, 2026 $15 and $20 calls - represented 3,134 contracts, with 1,567 contracts traded at each strike. The $15 call in that spread had an open interest of 16,662 contracts, while the $20 call showed zero open interest.
Other notable activity included the January 15, 2027 $10 call, which saw 2,498 contracts change hands compared with an open interest of 23,441 contracts. On the puts side, the October 16, 2026 $2 put recorded 2,277 contracts traded against an open interest of 973 contracts. The June 26, 2026 $13 call registered 1,580 contracts traded with an open interest of 986 contracts.
Share-price move and volatility
Shares of Sellas Life Sciences rose 14.2% to trade at $12.03 on Friday. The company’s three-month volatility increased by 24.56 percentage points to 250.53%. The three-month 90/110 skew rose by 18.58 percentage points to 23.08 percentage points.
Summary
By mid-afternoon on Friday, options turnover in Sellas Life Sciences was elevated, driven primarily by call buying and several concentrated strike-level trades, while the underlying stock posted a double-digit intraday gain and volatility measures expanded.
Key points
- Options volume totaled 66,504 contracts by 2:10 p.m. New York time on Friday, with calls comprising 50,150 contracts and puts 16,354 contracts.
- Highest single-option volume was in the June 26, 2026 $12 call (3,815 contracts); other heavy activity included a September 18, 2026 $15/$20 call spread and several further dated calls and a $2 put.
- The stock rose 14.2% to $12.03; three-month volatility and the 90/110 skew widened substantially.
Risks and uncertainties
- Elevated options turnover can correspond with increased price swings in the underlying stock, reflecting higher short-term volatility for Sellas Life Sciences.
- The presence of concentrated positions at specific strikes and spreads can create directional pressure or liquidity shifts in those strikes, which may affect market dynamics for the stock and its options.
- The rise in three-month volatility and skew signals greater uncertainty around near-term price outcomes for the company’s shares.
All numerical figures and descriptions above are taken from exchange data compiled as reported through the specified time on Friday.